Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Vardenafil improves exercise capacity in phase III trial in subjects with PAH

Sep. 14, 2010

New histamine H4 receptor ligand VUF-11488 to be tested in inflammation models

Sep. 13, 2010

Intranasal desmopressin ineffective in relieving renal colic pain

Sep. 13, 2010

INNOVATE-PCI trial data support entry of antiplatelet agent elinogrel in phase III trial

Sep. 13, 2010

Pharmacological profile supports evaluation of GSK-1427400 in chronic pain

Sep. 13, 2010

New gamma-secretase modulators show favorable properties in preclinical evaluation

Sep. 10, 2010

Prodrug delivers fenofibric acid and nitric oxide for cardiovascular disease treatment

Sep. 10, 2010

GSK-2188931 shows promise in rat model of myocardial infarction

Sep. 10, 2010

AGN-196923 alleviates neuropathic pain in animal models

Sep. 10, 2010

New alpha2C-adrenoceptor agonists display antinociceptive effects and cardiovascular safety in vivo

Sep. 9, 2010

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...